CohBar Announces Third Quarter 2016 Financial Results
11/14/2016 11:48:03 AM
MENLO PARK, Calif.--(BUSINESS WIRE)--CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), an innovative biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat diseases associated with aging and increase healthy lifespan, today reported financial results for the third quarter ended September 30, 2016.
“The advancement of our optimized MOTS-c analogs, CB4209 and CB4211, to IND-enabling activities during the third quarter was a significant milestone for CohBar, and an important step in demonstrating the potential of MBTs for the treatment of metabolic disorders underlying age-related diseases,” said Simon Allen, CohBar’s CEO.
comments powered by